2seventy bio, Inc. (TSVT)
May 13, 2025 - TSVT was delisted (reason: acquired by BMY)
5.00
0.00 (0.00%)
Inactive · Last trade price on May 12, 2025
2seventy bio Revenue
2seventy bio had revenue of $22.94M in the quarter ending March 31, 2025, with 84.46% growth. This brings the company's revenue in the last twelve months to $48.37M, down -32.07% year-over-year. In the year 2024, 2seventy bio had annual revenue of $37.86M, down -62.28%.
Revenue (ttm)
$48.37M
Revenue Growth
-32.07%
P/S Ratio
5.42
Revenue / Employee
$744,077
Employees
65
Market Cap
266.15M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.86M | -62.53M | -62.28% |
Dec 31, 2023 | 100.39M | 8.89M | 9.72% |
Dec 31, 2022 | 91.50M | 36.97M | 67.81% |
Dec 31, 2021 | 54.52M | -193.60M | -78.03% |
Dec 31, 2020 | 248.12M | 203.83M | 460.15% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTSVT News
- 5 months ago - 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
- 6 months ago - 2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT - Business Wire
- 7 months ago - 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 7 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc. - PRNewsWire
- 7 months ago - Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal - Benzinga
- 7 months ago - Top 3 Health Care Stocks That May Keep You Up At Night In Q1 - Benzinga
- 7 months ago - Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters
- 7 months ago - 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire